HealthCare Global Enterprises Posts 16% Revenue Growth in Q2 FY27 Driven by Advanced Oncology Services and Capacity Expansion
EBITDA rises 17% to INR 1,425 million with improved margins despite wage cost impact; company adds 25 beds and introduces advanced therapies including CAR T-cell and MR-LINAC
HealthCare Global Enterprises Limited announced its unaudited financial results for Q2 FY27, reporting a 16% year-on-year revenue increase to INR 7,318 million. The growth was driven by a 9% rise in patient volumes and a 7% increase in average revenue per patient, supported by higher contribution from complex oncology treatments including a 37% increase in robotic surgeries. EBITDA grew 17% to INR 1,425 million with margins at 19.7%, despite wage revision costs. The company expanded capacity with 25 new beds and advanced clinical technologies including MR-LINAC and CAR T-cell therapy.
HealthCare Global Enterprises Limited
Earnings Call Transcript
HealthCare Global Enterprises Limited announced a 16% year-on-year revenue increase to INR 7,318 million for the quarter ended September 30, 2026, fueled by higher patient volumes and greater contribution from complex oncology treatments, including a 37% rise in robotic surgeries.
The company’s average revenue per patient rose 7% year-on-year, driven by favorable payor mix and a shift towards high-complexity treatments. Patient volumes increased by 9% overall.
EBITDA for Q2 FY27 reached INR 1,425 million, a 17% increase with margins improving to 19.7%. This growth occurred despite an approximate INR 60 million wage revision expense in Karnataka; excluding this, EBITDA growth exceeded 20%.
HealthCare Global’s newest facility in North Bengaluru reduced its EBITDA loss to INR 61 million as clinical ramp-up and capacity utilization improved.
Among regional clusters, South India contributed INR 2,941 million with 18% growth, the West cluster generated INR 3,147 million growing 10%, and the East cluster achieved INR 928 million, up 23%. International operations in Kenya saw 54% revenue growth to INR 302 million, driven by expanded radiation and medical oncology services.
During the quarter, the company added 25 operational beds across Kenya, Kolkata, and Nagpur, totaling 146 beds added in the first half of FY27. Technological enhancements included commissioning MR-LINAC radiation therapy, cardiac surgical robotics, and clinical milestones such as first CAR T-cell therapy at Ahmedabad and multiple advanced robotic surgeries and diagnostics across centers.
Highlights
- Q2 FY27 revenue at INR 7,318 million, up 16% year-on-year.
- EBITDA increased 17% to INR 1,425 million with 19.7% margins despite wage cost impact.
- Robotic surgeries increased 37% year-on-year, bolstering complex oncology treatment revenue.
- North Bengaluru hospital narrows EBITDA loss to INR 61 million with improved utilization.
- 25 new operational beds added in Q2, total 146 beds in H1 FY27 expansion.
- Kenya operations revenue up 54% supported by new radiation machine and added beds.
Key Data Snapshot
What happened
- HealthCare Global Enterprises reported a 16% increase in revenue for Q2 FY27 to INR 7,318 million driven by higher patient volumes and revenue per patient.
- EBITDA grew 17% to INR 1,425 million with margins at 19.7%, despite employee cost increments due to wage revisions.
- Robotic oncology surgeries rose by 37%, contributing to growth in revenue from complex procedures.
- The newer North Bengaluru hospital continued to reduce its EBITDA loss to INR 61 million.
- International Kenya operations delivered 54% revenue growth supported by new radiation therapy equipment and bed capacity.
- Company expanded operational capacity by adding 25 new beds during the quarter across Kenya, Kolkata, and Nagpur.
Key details
- Average revenue per patient increased by 7% year-on-year aided by favorable payor mix and treatment complexity.
- Non-institutional revenue increased by 21%, improving its share to 69% of total revenue.
- South cluster contributed INR 2,941 million revenue with 18% growth, West cluster INR 3,147 million with 10% growth, and East cluster INR 928 million with 23% growth year-on-year.
- Advanced treatments introduced include MR-LINAC adaptive radiation therapy, CAR T-cell therapy, robotic breast and spine surgeries, and precision clinical diagnostics.
- Incremental employee costs from Karnataka Wage Act 2026 revision impacted margin expansion by approximately INR 60 million.
- New beds and advanced medical technology deployments underline focus on capacity and clinical capability enhancement.
Strategic context
- The company focuses on profitable growth, asset utilization, clinical differentiation, and optimizing revenue mix.
- Efforts emphasize increasing contribution from high-end oncology procedures and favorable payor mix.
- Strategic expansion in non-institutional services and capacity reflects intent to improve revenue quality and operational efficiency.
- Technological and clinical milestones reinforce positioning as a specialized oncology care provider with advanced treatment capabilities.
Highlights
- Q2 FY27 revenue at INR 7,318 million, up 16% year-on-year.
- EBITDA increased 17% to INR 1,425 million with 19.7% margins despite wage cost impact.
- Robotic surgeries increased 37% year-on-year, bolstering complex oncology treatment revenue.
- North Bengaluru hospital narrows EBITDA loss to INR 61 million with improved utilization.
- 25 new operational beds added in Q2, total 146 beds in H1 FY27 expansion.
- Kenya operations revenue up 54% supported by new radiation machine and added beds.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Sunrakshakk Industries India Limited Posts INR 265.17 Crores Revenue with 130% PAT Increase in Q2 FY27
Sunrakshakk Industries India Limited reported its Q2 FY27 financial results with revenue of INR 265.17 crores and a profit after tax of INR 16 crores, reflecting year-on-year growth of 119.20% in revenue and 130.10% in PAT, supported by expansion in its FMCG, FMCG intermediates, and edible segments.
Read Full StoryReligare Enterprises Posts INR 4,717 Crores Income and INR 145 Crores Loss After Tax in H1 FY27, Resumes Lending and Strengthens Board
Religare Enterprises Limited has reported consolidated total income of INR 4,717 crores and a loss after tax of INR 145 crores for the half-year ending September 30, 2026, marking a 19% increase in income year-on-year. The company is transitioning from preparation to execution phase by strengthening its board with RBI-approved promoter and shareholder directors, resuming lending through Religare Finvest, and advancing growth in its core financial services and insurance businesses.
Read Full StoryBlack Box Limited Posts Record Q2 FY27 Revenue of INR 1,936 Crores and Expands Order Backlog to $1.04 Billion
Black Box Limited reported its highest-ever quarterly revenue of INR 1,936 crores for Q2 FY27, marking a 22% year-on-year increase, alongside an 88% year-on-year growth in its order backlog, which reached $1.04 billion as of September 2026. Data center order bookings crossed $250 million during H1 FY27, signaling strong momentum in hyperscale digital infrastructure projects.
Read Full Story